久久一区二区三区四区_欧美高清dvd_日韩欧美在线看_国产精品欧美一区二区_av天天看_欧美精品免费观看二区

美國Biogen Idec    
Biogen主要從事治療淋巴瘤、多發(fā)性硬化癥、類風濕性關節(jié)炎等病癥的藥物的探索、開發(fā)、制造及銷售。
百健艾迪公司成立于１９７８年，在全球創(chuàng)新治療藥物發(fā)現(xiàn)、開發(fā)、制造和商業(yè)化領域具有領先地位。該公司針對淋巴瘤、多發(fā)性神經中樞硬化、風濕性關節(jié)炎的產品目前在全世界９０多個國家銷售。兩位創(chuàng)始人先后獲得諾貝爾獎。２００７年百健艾迪公司在中國上海設立了代表處。
2015年

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion.

Currently, the company markets three major therapies and its product development pipeline includes 20 products in Phase 2 clinical trials and beyond. Our major products include TYSABRI? (natalizumab), the most recently approved treatment for relapsing forms of MS; AVONEX? (Interferon beta-1a), the No. 1 prescribed therapy for relapsing forms of MS worldwide; and RITUXAN? (rituximab), the world's most prescribed therapy for non-Hodgkin's lymphoma and marketed for the first time in 2006 for rheumatoid arthritis. AVONEX and RITUXAN have for years ranked among the top 10 biotechnology products sold globally. In recent years, we also have leveraged our core capabilities to expand development into promising new therapeutic areas, such as cardiovascular disease and hemophilia.

Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. We have additional offices in the U.S., Canada, Australia, Japan and throughout Europe.

Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.

Biogen Idec attracts world-class talent to fuel its global growth, and the company currently employs more than 4,200 people worldwide.